Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Thuflep TLF: initial experience and results of prostate laser enucleation with fibrous thulium laser (TLF)
While prostate laser enucleation is being confirmed as the new gold standard for surgical management of benign prostate hypertrophy, the holmium:Yag laser is currently the most widely used. A new laser technology, the fibrous thulium laser (TFL), has recently appeared with clearly superior results for lithotripsy. The question therefore arises of the surgical and functional results of the use of fibrous thulium for prostate enucleation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL | self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms) | MONTH 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of post-operative complications | post operative complications : urethral stenosis, prostate bed sclerosis, overactive bladder, urinary incontinence, erectile dysfunction | MONTH 6 |
| duration of intervention |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
all patients treated at clinique saint hilaire Rouen with Thuflep, who consent
Not provided
| Name | Affiliation | Role |
|---|---|---|
| BENOIT MALVAL | Clinique Saint-Hilaire | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique Saint Hilaire | Rouen | 76000 | France |
Not provided
| ID | Term |
|---|---|
| D011470 | Prostatic Hyperplasia |
| ID | Term |
|---|---|
| D011469 | Prostatic Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
in minutes
| POST SURGERY HOUR 24 |
| bloodloss assessment | measurement of haemoglobinemia | Day 1 |
| max flow assessment | measured with urinary flowmeter in ml/sec | MONTH 12 |
| max flow assessment | measured with urinary flowmeter | MONTH 6 |
| max flow assessment | measured with urinary flowmeter | MONTH 3 |
| max flow assessment | measured with urinary flowmeter | MONTH 1 |
| post-void residual (PVR) urine test | ml | MONTH 12 |
| post-void residual (PVR) urine test | ml | MONTH 6 |
| post-void residual (PVR) urine test | ml | MONTH 3 |
| post-void residual (PVR) urine test | ml | MONTH 1 |
| erectile dysfunction assessment | self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction | MONTH 12 |
| erectile dysfunction assessment | self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction | MONTH 6 |
| erectile dysfunction assessment | self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction | MONTH 3 |
| erectile dysfunction assessment | self reported International Index of Erectile Function 5 score(IIEF-5) from 5 : severe erectil dysfunction to 25 : no erectile dysfunction | MONTH 1 |
| quality of life assessment | self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health) | MONTH 12 |
| quality of life assessment | self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health) | MONTH 6 |
| quality of life assessment | self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health) | MONTH 3 |
| quality of life assessment | self reported Short Form (36) Health Survey score(SF-36) from 0 to 100 (good health) | MONTH 1 |
| urinary incontinence Assessment | self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks | MONTH 12 |
| urinary incontinence Assessment | self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks | MONTH 6 |
| urinary incontinence Assessment | self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks | MONTH 3 |
| urinary incontinence Assessment | self reported International Consultation on Incontinence: short questionary score (ICIQ) from 0 : no leaks, to 19 : major leaks | MONTH 1 |
| prostatic specific antigen in ng/mL level evolution | ng/ml | MONTH 1 |
| Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL | self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms) | MONTH 1 |
| Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL | self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms) | MONTH 3 |
| Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL | self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms) | MONTH 6 |
| PATIENT GLOBAL IMPRESSION OF IMPROVEMENT | SELF REPORT SATISFACTION QUESTIONARY FROM 1 (better condition ) to 7 ( worse condition) | MONTH 1 |
| PATIENT GLOBAL IMPRESSION OF SEVERITY | SELF REPORT SATISFACTION QUESTIONARY FROM 1( normal )to 4 (severe ) | MONTH 1 |
| D052801 |
| Male Urogenital Diseases |